Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmadzay Zohra Faizy, Ørnbjerg Lykke Midtbøll, Østergaard Mikkel, Jensen Kasper Yde, Jørgensen Jacob Brauner, Heberg Jette, Loft Anne Gitte, Michelsen Brigitte, Jones Gareth T, Hellamand Pasoon, Møller-Bisgaard Signe, Shoae Kazemi Mehrdad, Karimi Reikandeh Parham, Závada Jakub, Horák Pavel, Bernardes Miguel, Vieira-Sousa Elsa, Castrejón Isabel, Otero-Varela Lucía, Codreanu Catalin, Kuusalo Laura, Rantalaiho Vappu, Regierer Anne C, Reich Andreas, Möller Burkhard, Micheroli Raphael, Mielnik Pawel, Provan Sella Aarrestad, Lass Karin, Vorobjov Sigrid, Rotar Ziga, Pirkmajer Katja Perdan, Iannone Florenzo, Conti Fabrizio, Gudbjornsson Bjorn, Di Giuseppe Daniela, van de Sande Marleen, Macfarlane Gary J, Yarkan-Tuğsal Handan, Glintborg Bente, Hetland Merete Lund
Аннотация
METHODS: Patients with PsA initiating a first b/tsDMARD treatment in 2015 or later were identified in eight European rheumatology registries. Patients with information on five cardiometabolic comorbidities (obesity, dyslipidaemia, diabetes, hypertension, ischaemic heart disease) at treatment start (baseline) were included. All analyses were conducted according to patients' comorbidity burden (count: 0/1/≥2) and status (presence/absence of each comorbidity). Patient characteristics and prescription patterns were described. Twelve-month treatment retention rates were estimated and compared using Kaplan-Meier plots, log-rank tests and multivariable Cox regression analyses.
RESULTS: Among 5299 patients, 36% had at least one cardiometabolic comorbidity. Patients with comorbidity were older, had higher disease activity and more disability. Regardless of comorbidity, most patients were prescribed a tumour necrosis factor inhibitor (76%). The use of interleukin-17 inhibitors increased with comorbidity burden (0/1/≥2 comorbidities: 13%/18%/19%), whereas Janus kinase inhibitor use declined (2.3%/1.6%/0.8%). Retention rates were marginally lower with higher comorbidity burden (80%/76%/78%) (log-rank, p=0.036) and obesity (absent 79% vs present 77%) (log-rank, p=0.04). The risk of treatment withdrawal was only marginally higher in patients with higher comorbidity burden (one comorbidity: HR 1.19; 95% CI 1.02 to 1.40; ≥2 comorbidities: HR 1.18; 0.98 to 1.42).
CONCLUSION: Patients with cardiometabolic comorbidities had higher disease activity at treatment initiation of the first b/tsDMARD. Prescription patterns varied with comorbidity burden. Cardiometabolic comorbidity burden, especially obesity, was associated with marginally lower treatment retention.